High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: Tumor responses and toxicities

Oncology Letters

Volumn 6, Issue 5, 2013, Pages 1514-1520

  Huang, Bing Shen ^a   Tsang, Ngan Ming ^a   Lin, Shi Ming ^a   Lin, Deng Yn ^a   Lien, Jau Min ^a   Lin, Chen Chun ^a   Chen, Wei Ting ^a   Chen, Wan Yu ^b,c   Hong, Ji Hong ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Hepatocellular carcinoma; Hypofractionated; Radiotherapy; Toxicities

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN;

ADULT; AGED; ARTICLE; ASCITES; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; DOSE RESPONSE; DUODENUM ULCER; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FUNCTION; MALE; PORTAL VEIN THROMBOSIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOFREQUENCY ABLATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; URETHROSCOPE; X RAY;

EID: 84884496912     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1582     Document Type: Article

References (38)

1. Venook AP, Papandreou C, Furuse J and de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15 Suppl 4: 5-13, 2010.
2. Liu CL and Fan ST: Nonresectional therapies for hepatocellular carcinoma. Am J Surg 173: 358-365, 1997.
3. Ye SL, Takayama T, Geschwind J, Marrero JA and BronowickiJP: Current approaches to the treatment of early hepatocellular carcinoma. Oncologist 15 Suppl 4: 34-41, 2010.
4. Khan KN, Yatsuhashi H, Yamasaki K, et al: Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol 32: 269-278, 2000.
5. Lin SM, Lin CJ, Lin CC, Hsu CW and Chen YC: Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54: 1151-1156, 2005.
6. Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442, 2003.
7. Park W, Lim DH, Paik SW, et al: Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 61: 1143-1150, 2005.
8. Kawashima M, Furuse J, Nishio T, et al: Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. JClin Oncol 23: 1839-1846, 2005.
9. Tse RV, Hawkins M, Lockwood G, et al: Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol26: 657-664, 2008.
10. Toronto UHN: Stereotactic Body Radiation Therapy (SBRT) Hepatocellular Carcinoma. Journal Available from: http://www.clinicaltrials.gov/ct2/show/NCT00914355?term=HCC+SBRT&rank=00914355 NLM Identifier: NCT00914355. Accessed April 25, 2012.
11. Desmet VJ, Gerber M, Hoofnagle JH, Manns M and ScheuerPJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19: 1513-1520, 1994.
12. No authors listed: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28: 751-755, 1998.
13. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
14. Pan CC, Kavanagh BD, Dawson LA, et al: Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 76: S94-S100, 2010.
15. Cheng SH, Lin YM, Chuang VP, et al: A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 14: 1025-1033, 1999.
16. Ingold JA, Reed GB, Kaplan HS and Bagshaw MA: Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 93: 200-208, 1965.
17. Russell AH, Clyde C, Wasserman TH, Turner SS and RotmanM: Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys 27: 117-123, 1993.
18. Lawrence TS, Dworzanin LM, Walker-Andrews SC, et al: Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine. Int J Radiat Oncol Biol Phys 20: 555-561, 1991.
19. Lawrence TS, Ten Haken RK, Kessler ML, et al: The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 23: 781-788, 1992.
20. Dawson LA, McGinn CJ, Normolle D, et al: Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 18: 2210-2218, 2000.
21. Park HC, Seong J, Han KH, Chon CY, Moon YM and Suh CO: Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 54: 150-155, 2002.
22. Liu MT, Li SH, Chu TC, et al: Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn J Clin Oncol 34: 532-539, 2004.
23. Seong J, Park HC, Han KH and Chon CY: Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int JRadiat Oncol Biol Phys 55: 329-336, 2003.
24. Liang SX, Zhu XD, Lu HJ, et al: Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer 103: 2181-2188, 2005.
25. Bae SH, Park HC, Lim do H, et al: Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellularcarcinoma. Int J Radiat Oncol Biol Phys 82: e603-e607, 2012.
26. Kwon JH, Bae SH, Kim JY, et al: Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 10: 475, 2010.
27. Dawson LA and Ten Haken RK: Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 15: 279-283, 2005.
28. Cheng JC, Wu JK, Lee PC, et al: Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 60: 1502-1509, 2004.
29. Cheng JC, Liu HS, Wu JK, Chung HW and Jan GJ: Inclusion of biological factors in parallel-architecture normal-tissue complication probability model for radiation-induced liver disease. Int JRadiat Oncol Biol Phys 62: 1150-1156, 2005.
30. Kim JH, Park JW, Kim TH, Koh DW, Lee WJ and Kim CM: Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 69: 813-819, 2007.
31. Chou CH, Chen PJ, Lee PH, Cheng AL, Hsu HC and Cheng JC: Radiation-induced hepatitis B virus reactivation in liver mediated by the bystander effect from irradiated endothelial cells. Clin Cancer Res 13: 851-857, 2007.
32. Liang SX, Zhu XD, Xu ZY, et al: Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 65: 426-434, 2006.
33. Xu ZY, Liang SX, Zhu J, et al: Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys 65: 189-195, 2006.
34. Levy I and Sherman M; Liver Cancer Study Group of the University of Toronto: Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 50: 881-885, 2002.
35. Ueno S, Tanabe G, Sako K, et al: Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 34: 529-534, 2001.
36. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171, 2002.
37. Llovet JM, Real MI, Montana X, et al: Barcelona Liver Cancer Group: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739, 2002.
38. Lin DY, Liaw YF, Lee TY and Lai CM: Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma-a randomized controlled trial. Gastroenterology 94: 453-456, 1988.